JAMA Dermatology publishes Phase 3 VALOR brepocitinib skin outcomes
JAMA Dermatology published skin-specific outcomes from the Phase 3 VALOR trial of brepocitinib in dermatomyositis, per TradingView News.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.